BJH - volume 14, issue 5, september 2023
J. Blokken PhD, PharmD
The EHA 2023 congress was not only the opportunity to present updates on immune therapeutic treatments in acute lymphoblastic leukaemia (ALL), but also was also the occasion to present some clinical updates of important clinical studies in this setting. Below, we will discuss some of the key take-away messages from both sessions.
(BELG J HEMATOL 2023;14(5):226–9)
Read moreBJH - volume 14, issue 5, september 2023
J. Blokken PhD, PharmD
EHA 2023 again featured a plethora of interesting oral abstracts and poster presentations in the field of acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). In this article, we will highlight some of the most promising data with regard to AML clinical studies, novel combinations in the treatment of AML and risk stratification. Furthermore, we will discuss some important clinical updates in the field of MDS.
(BELG J HEMATOL 2023;14(5):221–5)
Read moreBJH - volume 14, issue 5, september 2023
M. Delforge MD, PhD
The treatment of relapsed and refractory multiple myeloma (MM) currently undergoes a new (r-)evolution. Real-world data like those from the LocoMMotion study have confirmed the grim outcome of MM patients who have received ≥3 treatment lines or who are refractory to the current backbone treatments that include a proteasome inhibitor, an immunomodulatory drug (IMiD) and an anti-CD38 monoclonal antibody.1 The median progression-free survival (PFS) and overall survival (OS) of this heavily pre-treated patient population is around four months and their overall survival barely exceeds one year. Until recently, the treatment options for this patient population were very limited and consisted mostly of retreatment with the drugs that had already been given in earlier treatment lines.2 Currently, the recently introduced T-cell redirecting therapies are completely reshaping the treatment paradigm of relapsed and refractory MM (triple class exposed and mostly triple class refractory). These therapies include CAR-T cells, bispecific antibodies and to a lesser extent antibody drug conjugates. Whereas B-Cell Maturation Antigen (or BCMA) is the most frequently targeted surface antigen, other targets include G-Protein Coupled Receptor family C group 5 member D (or GPRCD). It was therefore no surprise that the oral sessions on treatment of MM were nearly completely dedicated to T-cell redirecting therapies. In the following article, the most recent insights presented at the EHA congress in Frankfurt are discussed.
(BELG J HEMATOL 2023;14(5):216–8)
Read moreBJH - volume 14, issue 5, september 2023
M. Maerevoet MD
This meeting provided confirmation of the impressive results and the safety of CART, for several histological entities of lymphoma provided by real-life cases.
(BELG J HEMATOL 2023;14(5):211–2)
Read moreBJH - volume 14, issue 5, september 2023
N. Granacher MD
The focus on CML this year was on how to improve patient’s eligibility and success of treatment free remission (TFR). The longest TFR follow-up comes from the STIM trial, Imatinib +/- Interferon (IFN), in which has been shown that at 7-year follow-up only 38% of patients maintain TFR.1 Previously, additional prognostic features such as IFN pre-treatment and increased NK cell count at baseline have been suggested to be associated with increased success of TFR however these are not always validated in larger cohorts. Several investigators are therefore looking at how to better define TFR eligible patients and at how to increase the TFR success rate.
(BELG J HEMATOL 2023;14(5):207–10)
Read moreBJH - volume 14, issue 5, september 2023
A. Janssens MD, PhD
Most of the selected abstracts deal with longer-term results of clinical trials already presented previously and urgent medical needs still existing in chronic lymphocytic leukaemia (CLL).
(BELG J HEMATOL 2022;14(5):201–6)
Read moreBJH - volume 14, issue 1, february 2023
N. Granacher MD
With the identification of novel therapeutic targets in different MPN and the movement of second-/third-line treatment upfront, the MPN therapeutic landscape is continuously changing. For Ph+ CML, additional genetic mutations are probably going to change our currently known risk stratification and determine choice of front-line treatment. In Ph- MPN, focus is on molecular response and disease modification and scientific evidence that this might actually have beneficial effect on patient outcome is gradually being gathered.
(BELG J HEMATOL 2023;14(1):10–5)
Read more
Top
